Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas 
Welcome,         Profile    Billing    Logout  
 11 Diseases   1 Trial   1 Trial   409 News 


123456»
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Journal:  ZNF480 Accelerates Chemotherapy Resistance in Breast Cancer by Competing With TRIM28 and Stabilizing LSD1 to Upregulate the AKT-GSK3?-Snail Pathway. (Pubmed Central) -  Dec 12, 2024   
    Ipragliflozin was identified as a small-molecule inhibitor of ZNF480 and LSD1 interaction that may block breast cancer progression...Mechanistically, ZNF480 accelerates proliferation and neoadjuvant chemotherapy resistance in breast cancer cells via the AKT-GSK3?-Snail pathway by interacting with and stabilizing LSD1 in a competitive manner within TRIM28. This research has implications for developing targeted drugs against chemotherapy resistance in breast cancer.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Preclinical, Journal:  Water and sodium conservation response induced by SGLT2 inhibitor ipragliflozin in Dahl salt-sensitive hypertensive rats. (Pubmed Central) -  Nov 4, 2024   
    A high-salt diet significantly increased systolic blood pressure, but ipragliflozin did not significantly change systolic blood pressure in normal- or high-salt groups. In conclusion, SGLT2 inhibitor ipragliflozin did not change fluid and Na+ balance regardless of basal fluid retention, suggesting the potential of SGLT2 inhibitors to maintain body water and Na+.
  • ||||||||||  Preclinical, Review, Journal:  Exploring the Anti-Cancer Potential of SGLT2 Inhibitors in Breast Cancer Treatment in Pre-clinical and Clinical Studies. (Pubmed Central) -  Jul 26, 2024   
    Ongoing and future clinical trials investigating the use of SGLT2 inhibitors, both as monotherapy and in combination with other agents, will be crucial in elucidating their translational potential and guiding their integration into comprehensive breast cancer care. Overall, SGLT2 inhibitors represent a novel and promising therapeutic approach with the potential to improve clinical outcomes for patients with various subtypes of breast cancer, including the aggressive and chemo-resistant TNBC.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Lusefi (luseogliflozin) / Taisho
    Journal:  The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors. (Pubmed Central) -  Jun 20, 2024   
    In vitro study, both inhibitors attenuated the lipopolysaccharide-induced activation of primary microglia, along with morphological changes toward an inactive form, suggesting the direct inhibitory effect of SGLT2 inhibitors on microglia. In summary, SGLT2i may directly prevent early pathogenic mechanisms, thereby potentially playing a role in preventing DR.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Effects of Ipragliflozin and Metformin on Hepatic Steatosis and Liver Fibrosis (Poster Hall (West A4-B2); 923) -  May 20, 2024 - Abstract #ADA2024ADA_2930;    
    Compared with metformin, ipragliflozin significantly improved multiple hepatic steatosis and liver fibrosis indexes, suggesting that ipragliflozin may alleviate hepatic steatosis, prevent liver fibrosis progression, and improve glycemic control. Therefore, it may prevent MASLD/MASH.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal:  A review regarding the article 'Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement.'. (Pubmed Central) -  May 2, 2024   
    It was discovered that ipragliflozin has the ability to prevent dysfunction of the endothelium, and this effect was connected with oxidative stress...It has been hypothesized that SGLT2 inhibitors may indirectly affect AMPK to reduce mammalian target of rapamycin (mTOR) activity. Numerous studies have demonstrated that SGLT2 inhibitors can activate AMPK by restoring the AMP/ATP balance in favor of AMP, which is assumed to be the mechanism by which these medications have positive effects on the cardiac structure and microvessel.
  • ||||||||||  Review, Journal:  SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations. (Pubmed Central) -  Nov 15, 2023   
    The SGLT2i dapagliflozin and sotagliflozin have been temporarily licensed for use by the European Medical Agency (EMA) as an adjunct to insulin therapy in adults with T1D with a body mass index of 27 kg/m2 or higher...However, due to side effects, EMA recommendation for SGLT2 use on T1D was withdrawn. Further studies will be needed to determine the safety of this therapy in T1D and to define the type of patient who can benefit most from these medications.
  • ||||||||||  Apleway (tofogliflozin) / Kowa, Takeda, Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Mounjaro (tirzepatide) / Eli Lilly
    Retrospective data, Review, Journal:  A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jun 14, 2023   
    The newest antidiabetic non-insulinic drugs are reported to be efficient in lowering HbA1c, but this effect depends between classes, molecules, or patients' age. The newest antidiabetic drugs are proven to be efficient molecules in terms of HbA1c decrease, weight reduction, and safety, but more studies are needed in order to characterize exactly their efficacy and safety profiles.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study. (Pubmed Central) -  Jun 5, 2023   
    The newest antidiabetic drugs are proven to be efficient molecules in terms of HbA1c decrease, weight reduction, and safety, but more studies are needed in order to characterize exactly their efficacy and safety profiles. Ipragliflozin add-on therapy can be a viable option for better glycaemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulphonylurea.
  • ||||||||||  Review, Journal:  The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. (Pubmed Central) -  Dec 23, 2022   
    However, studies of ipragliflozin and luseogliflozin, agents approved outside the United States (U.S.), reported different outcomes relative to pivotal trials and failed to realize benefits in the HFpEF population...In the U.S., high cost and administrative hurdles may contribute to decreased patient and clinician uptake of this drug class. Future trial results and clinical experience with SGLT2 inhibitors may lead to expanded use and greater uptake among patients with heart failure.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Preclinical, Journal:  SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis. (Pubmed Central) -  Dec 13, 2022   
    Collectively, these results reveal a novel effect of empagliflozin, a clinical hypoglycemic gliflozin drug, in inhibiting ferroptosis and enhancing skeletal muscle cell survival and paracrine function under hyperglycemic condition via restoring the expression of GPX4. This study highlights the potential of intramuscular injection of empagliflozin for treating diabetic HLI.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Trial completion, Trial primary completion date:  Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin (clinicaltrials.gov) -  Oct 4, 2022   
    P3,  N=170, Completed, 
    This study may be contributed to further in vitro and in vivo validation and the development of novel SGLT2 inhibitor for treating HF.Communicated by Ramaswamy H. Sarma. Recruiting --> Completed | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Preclinical, Journal:  SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in non-diabetic rats. (Pubmed Central) -  Aug 26, 2022   
    In conclusion, the osmotic diuresis of the SGLT2 inhibitor increased serum sodium concentration and the vasopressin-related stimulation of fluid intake and renal water retention maintained fluid balance, whereas the loop diuretic did not engage the compensatory vasopressin system. The data suggest differences in vasopressin and fluid homeostatic responses between SGLT2 inhibitors and loop diuretics.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
    Journal, IO biomarker:  Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy. (Pubmed Central) -  Aug 22, 2022   
    SGLT2 inhibitors have antiproliferation, anti-tumorigenesis, and anti-migration effects and may induce apoptosis in cancer cells. In addition, treatment with SGLT2 inhibitors resulted in the downregulation of selected genes in the Du-145 cell line.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Clinical, Journal:  Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes? (Pubmed Central) -  Jun 8, 2022   
    None of the participants experienced severe hypoglycemic events. In conclusion, the administration of an SGLT2i in addition to intensive insulin treatment in patients with T1D improves glycemic control and body mass, without increasing the incidence of hypoglycemia or DKA.
  • ||||||||||  Journal:  Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation. (Pubmed Central) -  Apr 5, 2022   
    In addition, for T2DM patients, 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 13.68 weeks for the plateau of effect on weight; 50 mg/day ipragliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight. This was the first study to explore effects of SGLT-2 inhibitors on weight in T2DM; meanwhile, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended, respectively.